Spirulina

QUICK REF

• Evidence: 4/5 cardiometabolic (LDL / BP / allergic rhinitis) · 3/5 oxidative stress / CRP / UC / MS / oral leukoplakia · 2/5 athletic performance / anemia / cognition · 1/5 cancer / hair / "detox"
• Dose: 1–2 g/day (allergic rhinitis) · 4–8 g/day (lipid / BP / metabolic syndrome) · 3–5 g/day (general nutritional support)
• Timing: AM with vitamin-C-rich meal. Split if >5 g/day. Avoid evening high-dose (mild stimulation in sensitive users).
• Lab/Monitor: Lipid panel + BP at 8–12 wk if using cardiometabolic. LFTs at 12 wk in high-dose. INR weekly × 4 wk if on warfarin. Ferritin/TSAT if hemochromatosis risk.
• Key interactions: Warfarin (↓ via vitamin K) · immunosuppressants (antagonism) · antihypertensives + diabetes drugs (additive, monitor for hypoglycemia / hypotension) · CYP2C9/2C19 weak inhibition.
• STATUS: CONDITIONAL — Strong evidence exists for cardiometabolic adjunct in dyslipidemia / stage-1 HTN when source-verified (microcystin + heavy-metal tested). AVOID absolute in PKU, active autoimmune disease (esp. dermatomyositis / lupus / pemphigus), organ transplant recipients, spirulina/seaweed allergy. SKIP for unproven claims (cognitive enhancement, cancer prevention, heavy-metal "detox" outside arsenic, hair growth, B12 replacement for vegans).

Clinical Summary

Spirulina is a filamentous cyanobacterium (blue-green microalgae) cultivated commercially as Arthrospira platensis or Arthrospira maxima. Dried biomass contains ~60–70% protein, 10–20% Phycocyanin (a blue photosynthetic pigment), 0.8–1.4% gamma-linolenic acid (GLA), carotenoids, and trace minerals. Its chromophore Phycocyanobilin (PCB) is a bilirubin structural analog that inhibits NADPH oxidase (NOX2/4) — the core pharmacological hypothesis, reviewed most comprehensively in Citi 2024 (OpenAlex W4399286992) and Diniz 2025 (PMID 41244839).

Evidence is dense but surrogate-endpoint-heavy: 18+ meta-analyses cover CRP, MDA, TAC, lipid panels, and BP. Zero MAs cover hard endpoints (MACE, mortality, fatty liver histology). Zero medical society guidelines (ACC/AHA, AASLD, ADA, AAAAI, NCCN) endorse Spirulina despite this evidence base — a significant efficacy–recommendation gap.

The most important 2024–2026 updates:

• GRADE-moderate BP reduction confirmed (Shiri 2025, PMID 39529406): SBP −4.41 mmHg, DBP −2.84 mmHg.
• Ulcerative colitis RCT positive (Moradi 2024, PMID 38424572) — first robust IBD RCT.
• Multiple sclerosis RCT positive (Karimi 2025, PMID 40877830) — 1 g/day improved hs-CRP and QoL.
• TOGETHER trial NEGATIVE for COVID-19 (Reis 2024, PMID 39232602) — punctures pandemic-era repurposing hype.
• Autoimmune flare signal consolidated (Weiner 2025 lupus scoping review PMID 41475897; Adv Rheumatol 2025 PMID 40087772) — documented dermatomyositis, pemphigus, lupus cases with 1-day to 1-year latency.
• FDA 2026 amended 21 CFR 73.530 — expanded spirulina extract as color additive, tightened heavy-metal specs (Pb, As, Hg, Cd).
• Novel delivery paradigm emerging: West China Hospital Phase 2 trials (NCT07040969 radiation mucositis; NCT07324018 esophagitis) use spirulina-derived exosomes rather than bulk biomass.
• Phase 3 Immulina trial n=492 completed Dec 2025 (NCT05447078) for viral resilience — results pending.

The most important negative finding: nothing in 2024–2026 rescues the cognitive, cancer, heavy-metal "detox" (outside arsenic), or hair-growth claims. All remain 1/5 or 2/5.

Indications & Evidence

Legend. Type: DC = direct causal · PC = probable causal · UCC = uncertain causal · BC = biomarker change (surrogate; max 3/5) · SE = sufficient effect · ME = modest/inconsistent effect · AHE = animal/human extrapolation (max 2/5) · OA = observational-association · RC = refuted claim · CF = correlation with confound · FA = fallacy/folk · NE = no evidence. BH: Bradford-Hill (of 9). Safety: -- no signal · MON monitor · WARN caution · AVOID contraindicated for this use.

Prescribing

• Form: Powder (best value, highest nutrient retention, 80–85% bioavailability). Tablets/capsules for convenience (75–85%). Phycocyanin-enriched extract (30–40% PCB by weight) for targeted antioxidant use only; loses whole-food profile.
• Route: Oral. No validated sublingual / topical / injectable applications outside experimental exosome delivery.
• Dose by indication: see Indications table above. General range 1–8 g/day; starting dose 1 g/day × 1 wk to assess GI tolerance, titrate up by 1–2 g/wk.
• Timing: AM with breakfast containing vitamin C (iron absorption 2–3× boost); split doses above 5 g/day to reduce GI effects; avoid evening >3 g in sleep-sensitive users.
• Cycling: None required. No tolerance, no downregulation. Continuous use up to 12 mo supported by trial data; traditional use (Chad, Mexico) centuries.
• Stop criteria: GI intolerance refractory to split-dosing · allergic reaction · new-onset rash or dyspnea · ALT/AST >2× ULN · INR instability on warfarin · autoimmune disease flare.

Condition-Specific Protocols

Hyperlipidemia (4/5)

• Start 4 g/day (2 g AM, 2 g PM with meals) × 1 wk → 8 g/day (4 g + 4 g) if tolerated.
• Recheck lipids at 12 wk. Expected LDL Δ ≈ −30 to −45 mg/dL; effect is smaller than low-dose statin but comparable to 10 mg rosuvastatin in some trials.
• Combine with Mediterranean/DASH diet; not monotherapy for LDL >190 mg/dL or familial hypercholesterolemia.

Hypertension (4/5)

• 4 g/day split (2 g AM, 2 g PM) × 8 wk minimum.
• Expected Δ: SBP ≈ −4 mmHg, DBP ≈ −3 mmHg (GRADE moderate).
• Monitor BP weekly × 1 mo if on antihypertensives — additive effect documented.
• Not indicated for resistant hypertension or stage 2 HTN as monotherapy.

Allergic rhinitis (4/5)

• 2 g/day (single AM dose) × 8–12 wk.
• Onset: 4–6 wk for noticeable improvement, 12 wk for maximum effect.
• Non-inferior to cetirizine in head-to-head RCT (Nourollahian 2020, PMID 32773785) with fewer anticholinergic side effects.
• Load 1 wk before expected allergen peak (e.g., 1 wk pre-spring pollen) if seasonal.

Ulcerative colitis (3/5)

• Start 1 g/day (capsule or powder in smoothie — easier on inflamed mucosa).
• Increase to 2 g/day over 2 wk if tolerated.
• Monitor CRP, fecal calprotectin every 4–8 wk.
• Discontinue if flare worsens, rash, or new systemic symptoms.
• Use as adjunct to 5-ASA / biologic — not monotherapy.

Multiple sclerosis (3/5)

• 1 g/day × 6 mo (Karimi 2025 RCT protocol, PMID 40877830).
• Monitor EDSS, hs-CRP, QoL at 3 and 6 mo.
• Coordinate with neurologist; do not combine without supervision with natalizumab / high-dose immunomodulators.

Oral leukoplakia / OSMF (3/5)

• 500 mg–1 g/day × 3–12 mo as adjunct to tobacco/pan cessation + intralesional steroid.
• Kerala Mathew 1995 protocol: 1 g/day × 12 mo — recurrence 45% after discontinuation so consider indefinite low dose.

Safety

Contraindications

Absolute.

• Phenylketonuria (PKU). Spirulina is ~4.5% phenylalanine by weight. 10 g/day adds ~450 mg Phe — unacceptable in classic PKU.
• Active autoimmune flare — esp. dermatomyositis, lupus, pemphigus. Documented case reports of flare onset 1 day to 1 year after initiation (Bax 2023; Adv Rheumatol 2025 PMID 40087772; Weiner 2025 scoping review PMID 41475897). Mechanism: Th1 skewing via phycocyanin + polysaccharide TLR4 activation.
• Known spirulina / cyanobacteria / seaweed allergy. Anaphylaxis case reports exist.
• Organ transplant recipients on immunosuppression — antagonism risk.

Relative (caution + monitoring).

• Warfarin / other anticoagulants. Vitamin K content may reduce efficacy; maintain consistent spirulina dose; INR weekly × 4 wk after starting/stopping.
• Severe renal impairment (GFR <30). High protein burden; cap at 3 g/day if used; monitor BUN/creatinine.
• Autoimmune disease in remission (MS, stable IBD, RA). Low dose (1 g/day) with close monitoring; discontinue if symptoms worsen.
• Gout / hyperuricemia. Purine content moderate; monitor uric acid.
• Hemochromatosis (HFE C282Y/H63D) / iron overload. Spirulina provides 20–40% bioavailable iron; in iron-loaders, avoid daily high-dose.
• Pregnancy & lactation. No controlled human data. Microcystin teratogenicity documented in animals. Avoid absent third-party-tested clean product; if used, <3 g/day with CoA.
• G6PD deficiency. Theoretical concern from oxidant cycling; avoid high-dose during acute illness.

Adverse Effects

Drug Interactions

FAERS Signal Analysis (2024-04-17 snapshot)

Interpretation: FAERS is NOISE, not signal. Spirulina appears in 477 FAERS reports, but zero as a suspect drug — it is always concomitant food supplement alongside suspect pharmacologic agents (rivaroxaban, lenalidomide, atorvastatin, abemaciclib, denosumab, elacestrant, omalizumab). This pattern is a well-characterized artifact of surgical/oncology/cardiology polypharmacy co-reporting and matches the supplement FAERS-noise pattern.

Phycocyanin: 0 reports. Arthrospira: 0 reports.

Conclusion. OpenFDA contains no safety signal attributable to oral spirulina pharmacology. The real safety axes are contamination (microcystin, BMAA, heavy metals) and autoimmune flare (documented in case series outside FAERS) — neither captured by this dataset.

Quality & Contamination — The Primary Safety Axis

Contamination drives most real-world harm, not inherent pharmacology.

• Heavy metals. USP limits: Pb <2 ppm, As <0.5 ppm, Hg <0.1 ppm, Cd <0.5 ppm. 2024 Nutraceuticals World testing: 7/7 Amazon no-name brands failed Prop 65 (lead 1.5–6× limit).
• Microcystins. WHO drinking-water limit 1 μg/L; product limit commonly 1 μg/g. French ANSES 2023 survey: 99%+ small-scale French producers compliant. Open-pond Chinese and wild-harvested Klamath products highest risk.
• BMAA (β-methylamino-L-alanine). Arthrospira itself is not a major BMAA producer under controlled cultivation; contamination from co-cultured cyanobacteria has been reported at low ppb. Cox et al. Guam ALS-PDC hypothesis remains contested; no definitive causal link to commercial spirulina consumption + ALS established 2026.
• Cross-species contamination. Klamath Lake products historically co-contain Aphanizomenon flos-aquae (microcystin-positive). Arthrospira monoculture = safer.

2026 FDA rule (21 CFR 73.530, amended Feb 2026): expanded spirulina extract as color additive to general foods; tightened heavy-metal specs; concluded no safety concern on cumulative C-phycocyanin exposure up to 1.14 g/person/day. Microcystin remains a producer-side GMP responsibility, not FDA-mandated. Effective date delayed March 2026 pending labeling.

Special Populations

Synergies & Stacking

Antagonisms. High-dose Calcium (>500 mg) — ↓ iron absorption 20–30% (space 2–3 h). Supplemental Iron — competition for absorption (space 2 h). High-dose Zinc (>25 mg) — modest absorption competition.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer. This section catalogues self-reports from Reddit, Longecity, LowToxinForum, YouTube, blogs, and East Asian health communities. It is NOT clinical evidence. Folk claims are explicitly separated from RCT findings. Sample sizes are approximate (thread/report counts, not controlled populations).

Source Communities

• Reddit: r/Supplements, r/Nutrition, r/Biohackers, r/Nootropics, r/vegan, r/AllergicRhinitis, r/raypeat (anti), r/PCOS, r/MTHFR (N ~100+ threads over 10 yr).
• Longecity: classic "Spirulina turns me into Superman" thread (~10–20 active threads).
• LowToxinForum / Ray Peat circles: negative skew (PUFA / GLA concerns).
• YouTube / blogs: Wellness Mama (+), Chris Kresser (−), Mark's Daily Apple (−), Rhonda Patrick (absent), Peter Attia (absent).
• East Asian: Japan (DHC, FANCL — mainstream beauty angle), Taiwan (FEBICO producer), China (Chenghai / Yunnan domestic), Korea (chlorella > spirulina).
• Indian practitioner: dental/oral medicine use for OSMF in Kerala, Maharashtra, Karnataka.

Top 5 Consistently Reported Positive Effects

1. Smooth AM energy at 3–8 g without caffeine-jitter.
2. Allergic rhinitis relief (2 g+ / 4–8 wk) — aligns with clinical evidence.
3. Mild BP lowering — self-tracked at home — aligns with MA.
4. Reduced post-meal glucose spikes on CGM at 4–8 g.
5. "Mental clarity" / motivation (placebo-vulnerable; not validated in RCTs).

Top 5 Consistent Complaints

1. Fishy taste / fishy burps (powder) — compliance failure; users switch to tablets/capsules.
2. GI upset, bloating, nausea first 1–2 weeks.
3. Breakouts around jaw/mouth (mechanism unclear — iodine vs allergy vs concomitant).
4. Headache + fatigue in a subset (community labels "die-off" — unfalsifiable).
5. Autoimmune concerns — documented case reports (DM, lupus, pemphigus); Hashimoto's users split on tolerability.

Folk Dosing vs Clinical Dosing

• Clinical RCT range: 1–8 g/day; 1–2 g for allergic rhinitis; 500 mg–1 g for oral leukoplakia.
• Folk consensus: 3–5 g AM (sits within clinical range).
• Folk outliers: 10–15 g routine, 20–50 g "heroic dose" (Longecity) — no clinical support.

Folk Claims Without Clinical Backing

• Heavy metal "chelation dump" in healthy adults (only human evidence is arsenic, PMID 16615668).
• B12 source for vegans — FALSE. ~80% pseudocobalamin, may even competitively inhibit true B12 uptake.
• Protein replacement — impractical at realistic doses (20 g protein ≈ 30 g powder).
• Nootropic / mental clarity — placebo-dominant.
• Radiation detox.
• DOMS reduction in recreational lifters.
• Hair growth.
• "Die-off" reactions as proof of detox (unfalsifiable).

Clinical Effects Folk Users Under-Appreciate

• Lipid profile improvement (strongest MA signal).
• Fasting glucose reduction in T2DM adjunctive use.
• Oral leukoplakia / OSMF regression (Indian trial literature).
• IL-4 suppression mechanism in allergic rhinitis (explains their own experience).
• Diastolic BP reduction.

Brand Consensus (Biohacker-Trusted)

1. Nutrex Hawaii / Pure Hawaiian Spirulina Pacifica (Cyanotech) — repeatedly passes ConsumerLab; microcystin non-detect; premium cost accepted.
2. Earthrise (California; Cyanotech-linked) — widely trusted.
3. FEBICO (Taiwan) — export-grade clean profile.
4. FANCL / DHC (Japan) — additive-free; trusted domestically.
5. Parry Organic Spirulina (India) — with CoA only.

Avoid. Generic Amazon "organic" spirulina without third-party testing. 2024 testing: 7/7 Amazon no-name brands failed Prop 65 lead limits. Wild-harvested Klamath Lake products (Aphanizomenon cross-contamination).

Red Flags & Skepticism Notes

• ENERGYbits: aggressive influencer seeding; "algae tabs for everything" category creep.
• Herbalife: FTC $200M settlement 2016 (pyramid-adjacent); algae / greens products in their ecosystem.
• Cyanotech: produces Hawaiian supply AND funds its own contamination comparison testing vs competitors — conflict of interest, though findings plausibly correct.
• Affiliate-driven "superfood" review sites (Royal Spirulina, SuperfoodWorld, etc.) recycle identical copy.
• French industry funding: Virsolvy 2025 SpiruSil (silicon-enriched) arterial-function RCT in healthy elderly was industry-sponsored — read with conflict-of-interest lens (PMID 40077730).

Folk vs Clinical Reality Check

Folk experience largely aligns with clinical evidence for allergic rhinitis, BP, and cardiometabolic markers — these are the claims that survive scrutiny. Folk experience diverges from clinical evidence on detox, B12, protein, cognitive enhancement, and hair — these are marketing artifacts. The honest folk signal of autoimmune flare preceded the 2025 scoping review confirmation.

Deep Dive

Molecular Composition

• Protein 60–70% dry weight. Digestibility 84–86%. All essential amino acids; leucine high.
• Phycocyanin 10–20% dry weight (commercial high-quality >10%; phycocyanin extracts 30–40%).
• Phycocyanobilin (PCB) — chromophore of phycocyanin; structural analog of biliverdin → biliverdin reductase substrate → bilirubin-mimetic antioxidant (McCarty 2007 PMID 18158824).
• GLA 0.8–1.4% — rare plant source of gamma-linolenic acid.
• Carotenoids — β-carotene, zeaxanthin, cryptoxanthin.
• Chlorophyll-a 1–2% (source of green stool).
• Sulfated polysaccharides — immunomodulatory.
• B-vitamins (B1, B2, B3, B6); B12 ~80% pseudocobalamin (inactive in humans).
• Minerals — non-heme iron (20–40% bioavailable with vitamin C), calcium, magnesium, potassium, zinc, selenium.
• Cell wall — peptidoglycan-like (thinner than plant; no cellulose) → high digestibility.

Core Mechanisms (with clinical-translation status)

Pharmacokinetics

• Phycocyanin absorption: intact across intestinal epithelium; peak plasma 2–4 h; metabolized by heme oxygenase to PCB (active metabolite); biliary + urinary excretion.
• Protein/AA: digested stomach+SI; amino acids bypass liver first-pass.
• Iron: 20–40% bioavailability with vitamin C; comparable to beef/egg in animals.
• Carotenoids: 10–20% conversion efficiency β-carotene → retinol.
• Stability: heat-sensitive >60°C (phycocyanin denatures); light-sensitive (UV degrades phycocyanin); pH-stable neutral-to-alkaline.

2024–2026 Trial Pipeline — Watch List

Ataraxia Verdict (as of 2026-04-17)

Hype Check

• "Superfood." Marketing term with no regulatory or nutritional meaning. Spirulina is nutrient-dense but not categorically superior to animal liver, oysters, or diverse leafy greens.
• "Plant-based B12 source." FALSE — pseudocobalamin, inactive in humans, may even inhibit true B12.
• "Heavy metal detox." WEAK — only human RCT is chronic arsenicosis (single trial, 20 years unreplicated). Product itself can accumulate metals from bad sources.
• "Superman energy." Placebo-dominant; no controlled energy studies.
• "Ancient food of the Aztecs" = safe." Appeal to tradition. Aztec tecuitlatl and Chad dihé consumption are documented but do not constitute safety data.
• "Cancer cure." No human RCTs in oncology; in-vitro data only.

Evidence Classification (Mode 5 summary)

• DC (direct causal) 4/5: dyslipidemia, hypertension, allergic rhinitis.
• PC (probable causal) 3/5: oxidative stress biomarkers (surrogate cap), CRP (surrogate cap), UC, MS, oral leukoplakia/OSMF, arsenicosis, malnourished peds growth, periodontitis.
• ME (modest/inconsistent) 2/5–3/5: T2DM glycemic control, metabolic syndrome multi-component, athletic performance, weight loss, NAFLD.
• BC (biomarker only) 2/5–3/5: TAC, MDA, SOD upregulation, CRP, Hb, MCI.
• AHE (animal/human extrapolation, max 2/5): neuroprotection, cognitive enhancement, RA, cancer, non-arsenic heavy-metal detox.
• RC (refuted): B12 replacement for vegans; COVID-19 hospitalization benefit (TOGETHER trial).
• NE (no evidence): hair growth, detoxification outside arsenic.
• Star ceiling enforcement: all BC/AHE/RC/NE claims capped per taxonomy.

Evidence Gaps

• Zero hard-endpoint trials (MACE, mortality, histology, disability progression).
• Zero head-to-head vs statins or standard antihypertensives.
• Zero medical society guideline endorsement despite 18+ MAs.
• Pregnancy / lactation: no controlled data.
• Pharmacogenomics: entirely absent.
• Long-term safety >12 months: limited to observational / traditional-use.
• Immulina Phase 3 results (NCT05447078) pending — will clarify viral-resilience claim.
• BMAA / cyanotoxin chronic exposure: epidemiologic data thin.

Bias Flags

• Surrogate endpoint dominance. Most MAs report biomarker changes; clinical significance of a 3-mmHg BP drop or 40-mg/dL LDL drop on long-term cardiovascular events is inferred, not measured.
• Geographic skew. Trials concentrated in Iran, India, China, Egypt — useful signal but different patient profiles, different concomitant diets, different product sources.
• Industry-adjacent funding. Several landmark RCTs (Virsolvy 2025 SpiruSil; Cyanotech competitor testing) carry industry ties.
• Heterogeneity. 2024–2026 CRP MAs show I² up to 86.7% — effect size estimates unstable.
• Replication gap. Mathew 1995 oral leukoplakia and Misbahuddin 2006 arsenic RCTs are foundational but unreplicated at scale.
• Publication bias. Negative supplement trials underpublished historically; TOGETHER COVID RCT is a rare well-powered negative in the corpus.

Manipulation Flags

• Marketing claims outrun evidence for: detox, B12, protein source, cognitive enhancement, hair growth, cancer prevention, longevity. These lack human RCT support.
• MLM / pyramid-adjacent ecosystems: Herbalife ecosystem (FTC 2016), Youngevity, Reliv, Market America / Isotonix — all sell spirulina or phycocyanin at multiples of raw material cost.
• Affiliate review sites (Royal Spirulina, SuperfoodWorld) recycle identical copy across domains — astroturfing pattern.
• Industry concentration. Cyanotech (NASDAQ:CYAN) + DIC (Earthrise) + Chinese Yunnan producers dominate supply; raw material ~$5–10/kg bulk, retail $60–200/kg (10–30× markup).
• ENERGYbits aggressive direct-response + influencer seeding.
• Red-team from 10 angles:
  1. Logical consistency: cardiometabolic signal is internally consistent across MAs.
  2. Evidence quality: moderate (multiple MAs, GRADE moderate for BP).
  3. Cui bono pro-spirulina: global market ~$500M; Hawaiian + Chinese producers; vegan food industry.
  4. Cui bono anti-spirulina: statin manufacturers minor; pharma fearmongering low-intensity.
  5. Time horizon: benefits materialize at 8–12 wk; requires compliance.
  6. Steelman: honest nutrient-dense adjunct with modest real effects on hard-to-move metrics.
  7. Reversibility: high — effects fade 2–4 wk after discontinuation; no dependence.
  8. Second-order effects: contamination risk if bad sourcing; autoimmune flare in susceptible.
  9. Historical precedent: traditional use Chad/Mexico for centuries; modern supplementation from 1970s.
  10. Stranger test: would a new reader without social proof adopt this? Yes for cardiometabolic clear-indication use.

Decision Support

• Health utility score: 7/10. Well-evidenced for one primary domain (cardiometabolic), broad nutritional profile, low cost (<$30/mo), favorable safety in healthy adults with clean product, moderate compliance burden (fishy taste).
• Hell Yes or No (Sivers): Not "hell yes" across the board. Conditionally hell yes for: dyslipidemia-adjunctive therapy unwilling to start statin, stage-1 hypertension adjunct, seasonal allergic rhinitis sufferer wanting non-drug option.
• Opportunity cost: $15–40/mo, 2–3 capsules-worth of stack complexity, 8–12 wk patience to see effects, compliance discipline (taste).
• Verdict: CONDITIONAL.
  • ADD if: dyslipidemia / stage-1 HTN not yet on pharmacotherapy; seasonal allergic rhinitis needing non-drug option; general nutritional gap (athletic / recovery); oral leukoplakia / OSMF adjunct under dental supervision; UC/MS adjunct under specialist care.
  • SKIP for: cognitive enhancement, cancer prevention, "detox" (outside arsenic), hair growth, B12 for vegans, weight loss as primary goal, COVID-19 prophylaxis.
  • AVOID if: active autoimmune flare (esp. DM/lupus/pemphigus), PKU, organ transplant on immunosuppression, spirulina/seaweed allergy, pregnancy without CoA-tested product, anticoagulation without INR monitoring.
• Regret minimization: not having documented knowledge of spirulina is a mild regret; skipping this compound is low-regret (substitutes exist for most indications).

Bottom Line

Spirulina is a moderately evidenced, low-cost cardiometabolic adjunct whose honest value is in hyperlipidemia, stage-1 hypertension, and seasonal allergic rhinitis. Its marketing surface area vastly exceeds its real evidence. The primary safety axis is contamination (microcystin, heavy metals, BMAA) — buy only third-party-tested products, prefer Hawaiian or French ANSES-compliant sources. A secondary safety axis is autoimmune flare in susceptible individuals. PKU is an absolute contraindication. For most targeted clinical uses, better-studied alternatives exist (statins > spirulina for LDL; antihistamines > spirulina for AR onset time; IF you want a gentle multi-mechanism cardiometabolic nudge with nutritional side benefits, spirulina is reasonable). Do NOT use as B12 source, cancer therapy, or "detox."

Practical Notes

Brands (biohacker-trusted, no endorsement)

• Premium Hawaiian: Nutrex Hawaii (Pacifica); Pure Hawaiian (Cyanotech) — USP verified + independent microcystin testing.
• Mid-price US: Earthrise; NOW Foods (USP verified select lots); Swanson (passed ConsumerLab).
• Asia clean: FEBICO (Taiwan); FANCL, DHC (Japan); Parry Organic (India, with CoA).
• Budget + tested: Micro Ingredients (third-party tested lots).
• Avoid: Amazon no-name "organic" labels without CoA (2024: 7/7 failed Prop 65 lead); Klamath wild-harvest (AFA cross-contamination); MLM-only distribution.

Storage

• Room temperature 15–25°C; dark, opaque, airtight; pantry / cupboard.
• Shelf life: unopened 2–3 yr; opened powder 6–12 mo; tablets/capsules 18–24 mo; liquid 30–90 d refrigerated.
• Degradation signs: faded green → brown, rancid odor, clumping, mold — discard.

Palatability

• Powder: earthy / seaweed / mildly fishy — unpalatable to ~40% of first-time users.
• Masking that works: banana-mango smoothie, pineapple juice, chocolate protein shake, yogurt.
• Masking that fails: plain water, milk, coffee.
• Tablets/capsules: zero taste; most users default here at 1–3 g/day.
• Fishy burps are the #1 compliance complaint.

Exercise & Circadian

• AM dose preferred; aligns with digestive enzyme peak and iron-absorption breakfast window.
• Pre-workout 60–90 min: 2–4 g reduces exercise-induced oxidative stress.
• Post-workout within 2 h: 3–7 g combined with other protein sources.
• Evening: avoid >3 g in sleep-sensitive individuals.

Reference Ranges (for monitoring stack)

• Lipid panel: LDL, HDL, TG, non-HDL — recheck 12 wk after starting.
• BP: home-monitor 2× daily × 1 wk pre-start, then weekly × 4 wk.
• hs-CRP: baseline + 12 wk (signal, not target).
• ALT/AST: baseline + 12 wk in high-dose users or pre-existing hepatic issue.
• Ferritin + TSAT: baseline if iron-loading risk.
• INR: weekly × 4 wk if on warfarin.
• TPO antibodies: if starting in Hashimoto's — watch for flare.

Cost

Best value: non-organic powder from verified brand + vitamin C co-ingestion. Best for compliance at low dose: Hawaiian tablets.

Common Mistakes

• Dosing PM and blaming spirulina for insomnia.
• Using spirulina as primary B12 source (it is not).
• Expecting lipid or BP effects before 8–12 wk.
• Buying cheapest Amazon brand without CoA.
• Continuing during acute autoimmune flare.
• Using as sole protein source.
• Pairing with high-calcium meal (30–40% ↓ iron absorption).

What We Don't Know

• Hard endpoints. No MACE / mortality / histology trial has ever been done on Spirulina.
• Head-to-head pharmacotherapy. No RCT vs statin, vs losartan, vs nasal corticosteroid.
• Pharmacogenomics. Essentially zero formal PGx literature.
• Pregnancy / lactation. No controlled human data.
• Chronic BMAA exposure. Epidemiology thin; Arthrospira-specific risk unresolved.
• Microbiome mechanism in humans. Rodent-dominant; human microbiome trials preliminary.
• Exosome delivery paradigm. West China Hospital Phase 2 data (2026–2028) will determine whether engineered spirulina products have a place in radiation oncology.
• Immulina Phase 3 (NCT05447078). Results pending as of 2026-04-17 — will clarify viral-resilience signal.
• Autoimmune mechanism. Th1 skewing hypothesis is inferred; no controlled provocation data.
• Optimal phycocyanin content. Whole-food vs extract comparisons unclear; synergy claims unproven.
• Long-term safety beyond 12 months. Traditional-use evidence exists but not controlled.

References

Core Meta-Analyses & Systematic Reviews (2024–2026)

1. Shiri et al. 2025 — Phytother Res — GRADE MA BP reduction (SBP −4.41 mmHg, DBP −2.84 mmHg). PMID 39529406.
2. Hariri et al. 2026 — Front Nutr — CRP MA. PMID 41873104.
3. Fu et al. 2025 — Spirulina ± exercise cardiometabolic OW/Obesity (23 RCTs, n=1035). PMID 40655486.
4. Pinto-Leite et al. 2025 — Nutrients — Chlorella + Spirulina adjuvant CVD risk. PMID 40289965.
5. Casas-Agustench et al. 2025 — edible algae BP MA. PMID 40726022.
6. Shiri et al. 2025 — CV health MA. PMID 40953712.
7. CRP dose-response MA 2025. PMID 40330210.
8. Mishra et al. 2026 — children/adolescent growth SR/MA. PMID 41919083.
9. Sukmawati et al. 2025 — malnourished children growth SR/MA. PMID 41541825.
10. Lacurezeanu et al. 2025 — iron status SR. PMID 41255135.
11. Kazeminejad et al. 2025 — anthropometric indices GRADE SR/MA. PMID 39461896.
12. Jurek et al. 2025 — MASLD plant-based foods SR. PMID 41010543.
13. Bayo Jimenez et al. 2025 — Alzheimer's natural products SR. PMID 41226670.
14. Weiner et al. 2025 — Lupus Sci Med — immunostimulatory herbs autoimmune skin flare scoping review. PMID 41475897.
15. Adv Rheumatol 2025 — spirulina-induced autoimmunity case series. PMID 40087772.

Foundational Meta-Analyses

16. Serban et al. 2016 — Clin Nutr — lipid MA (7 RCTs, N=522). PMID 26433766.
17. Machowiec et al. 2021 — Hypertens Res — BP MA (5 RCTs, N=230). PMID 34578932.
18. Rahnama et al. 2023 — Front Nutr — umbrella lipid MA. PMID 37263369.
19. Karkos et al. 2007 — Evid Based Complement Alternat Med — clinical applications review. PMID 17125579.
20. Naeini et al. 2021 — PharmaNutrition — antioxidant MA (9 RCTs, N=415). PMID 34235823.
21. Shahraki Jazinaki et al. 2025 — Complement Ther Med — CRP MA. PMID 39752639.
22. Hamedifard et al. 2019 — Phytother Res — glycemic + lipoprotein MA in MetS. PMID 31359513.
23. Hatami et al. 2021 — J Diabetes Metab Disord — T2DM MA. PMID 34178867.
24. Ghanbari et al. 2022 — Curr Diabetes Rev — glycemic MA. PMID 34538515.
25. Moradi et al. 2019 — Complement Ther Med — obesity MA. PMID 31780031.
26. Zarezadeh et al. 2021 — Phytother Res — anthropometric MA. PMID 32967062.
27. Marles et al. 2011 — USP safety evaluation. PMID 21628364.
28. Wu et al. 2016 — Arch Toxicol — comprehensive mechanistic review. PMID 27259333.

Key RCTs (Landmark + 2024–2026)

29. Mathew et al. 1995 — Kerala oral leukoplakia RCT (45% CR vs 7%). PMID 8584455.
30. Misbahuddin et al. 2006 — Clin Toxicol — chronic arsenicosis RCT Bangladesh. PMID 16615668.
31. Cingi et al. 2008 — Eur Arch Otorhinolaryngol — allergic rhinitis DB-RCT. PMID 18343939.
32. Nourollahian et al. 2020 — Acta Otorhinolaryngol Ital — AR non-inferior to cetirizine. PMID 32773785.
33. Mao et al. 2005 — IL-4 suppression mechanism in AR. PMID 15857205.
34. Mulk et al. 2013 — OSMF vs pentoxifylline. PMID 24551724.
35. Karimi et al. 2025 — relapsing-remitting MS triple-blind RCT. PMID 40877830.
36. Moradi et al. 2024 — ulcerative colitis DB-RCT. PMID 38424572.
37. Nasab et al. 2025 — IBS-C heat-killed probiotic + spirulina RCT. PMID 40500692.
38. Reis et al. 2024 — TOGETHER COVID-19 RCT (NEGATIVE). PMID 39232602.
39. Aghasadeghi et al. 2024 — hospitalized COVID-19 smaller RCT. PMID 38655258.
40. Delfan et al. 2026 — HIIT + spirulina obese men. PMID 41850008.
41. Tayebi et al. 2025 — HIIT + spirulina insulin resistance. PMID 40123054.
42. Pour et al. 2026 — probiotic + spirulina soccer performance. PMID 40346383.
43. Gurney et al. 2025 — altitude lactate threshold (NEGATIVE ergogenic). PMID 40310870.
44. Akbarzadeh et al. 2025 — aerobic exercise + spirulina overweight women. PMID 40304664.
45. Virsolvy et al. 2025 — Si-enriched spirulina (SpiruSil) elderly (industry-sponsored). PMID 40077730.
46. Hossein et al. 2025 — circuit resistance + spirulina asprosin/appetite. PMID 39259404.
47. Jalali et al. 2025 — bioactive peptides periodontal flap surgery. PMID 40410376.
48. Dolly et al. 2024 — subgingival spirulina gel vs chlorhexidine periodontitis. PMID 40016818.
49. Krokidas et al. 2024 — spirulina Nigrita eccentric exercise damage. PMID 38892584.
50. Gronevalt et al. 2024 — Phase 2 PPI rebound dyspepsia. PMID 38401078.
51. Ali et al. 2024 — 14-d spirulina recreational cyclists (Hb ↑, no ergogenic). PMID 37807529.
52. Mazloomi et al. 2022 — NAFLD RCT. PMID 35154670.
53. Choi et al. 2022 — Korean SM70EE MCI DB-RCT. PMID 36145090.
54. Chaouachi et al. 2022 — rugby players muscle damage. PMID 35394687.
55. Chowdhar et al. 2025 — OSMF vs lycopene adjunct IL-steroid. PMID 41585975.
56. Rai et al. 2023 — OSMF network MA. PMID 36781110.
57. Gopinath et al. 2022 — OSMF network MA. PMID 36013221.

Mechanism & Pharmacology

58. McCarty 2007 — phycocyanobilin → NADPH oxidase inhibition mechanistic. PMID 18158824.
59. Diniz et al. 2025 — Front Pharmacol — smooth muscle disorders pharmacology review. PMID 41244839.
60. Citi et al. 2024 — Nutrients — C-phycocyanin nutraceutical review. (OpenAlex W4399286992)
61. Savranoglu et al. 2013 — CYP2C9/2C19 in-vitro inhibition. PMID 24035960.
62. Deng & Chow 2010 — Cardiovasc Ther — CV mechanisms review. PMID 20633023.
63. Shioji et al. 2021 — Nutrients — bioavailability metabolomics animal. PMID 33807280.
64. Niture et al. 2025 — cyanotoxins neuroblastoma cell viability. PMID 41424770.
65. Yu et al. 2025 — salinity-biostimulant productivity + biosafety. PMID 39778684.
66. Nikolova et al. 2024 — Bulgarian bioreactor metabolomics. PMID 38398682.

Safety & Case Reports

67. Bax et al. 2023 — Clin Rheumatol — dermatomyositis case report. (no PMID surfaced in 2026 reverification)
68. Ali et al. 2015 — RA animal model vs silymarin. (Ali BM, J Herbmed Pharmacol)
69. Yang et al. 2025 — engineered probiotic phycocyanin delivery RA model. PMID 40360534.
70. Gogna et al. 2023 — microcystin/BMAA/heavy metal contamination review. PMID 35916491.

Trials to Watch (not yet published)

71. NCT05447078 — Immulina spirulina extract Phase 3 viral resilience, n=492, completed 2025-12-08.
72. NCT07040969 — West China Hospital spirulina-exosome radiation oral mucositis Phase 2, n=70.
73. NCT07324018 — West China Hospital spirulina-exosome radiation esophagitis Phase 2, n=70.
74. NCT07263217 — cholangiocarcinoma/hepatectomy recovery (Zhejiang).
75. NCT06770283 — liver cirrhosis (Zhejiang).
76. NCT07173062 — CVD markers + microbiome (Porto).
77. NCT06936202 — depression/mental acuity.
78. NCT06391957 — exercise muscle damage.